Skip to main content
S&P 5007,690.73+0.41%DOW51,966.03-0.07%NASDAQ26,430.89+1.11%BTC$81,410.00-1.14%ETH$2,383.80-1.53%GOLD$4,143.00-0.41%OIL$100.57+2.06%
Smart Investors Daily
SID Premium
GH

NASDAQ · GH

Guardant Health, Inc.

Healthcare · Medical - Diagnostics & Research

$157.88

Down-$0.72 (-0.45%)

Updated Oct 20, 2026, 12:11 PM

SID Score

6.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
12.58B
P/E ratio
-31.72
Dividend yield
0.00%
52-week range
$64.00 – $191.05
Volume
1.87M
Avg. volume
2.66M

Price performance · GH

GH price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 19, 2026

GH closed at $157.88 after 21 trading sessions, down 9.20% for the selected period.

Last close
$157.88
Period change
-9.20%
Period low
$157.88
Period high
$187.22
Daily close
View OHLC price history
GH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 19, 2026$160.65$163.91$155.00$157.881.87M
Oct 16, 2026$165.88$168.47$157.435$158.601.98M
Oct 15, 2026$160.78$168.86$158.998$165.881.33M
Oct 14, 2026$159.89$166.16$159.00$162.991.28M
Oct 13, 2026$161.945$164.53$158.36$162.0851.3M
Oct 12, 2026$168.26$168.69$158.46$162.791.56M
Oct 9, 2026$166.03$170.8099$166.03$167.471.52M
Oct 8, 2026$166.24$167.275$161.61$165.561.6M
Oct 7, 2026$166.50$171.55$165.00$168.332.2M
Oct 6, 2026$188.00$191.05$170.05$170.693.39M
Oct 5, 2026$177.45$187.69$176.37$187.221.75M
Oct 2, 2026$173.32$179.17$172.00$177.801.65M
Oct 1, 2026$177.17$180.91$173.96$174.751.96M
Sep 30, 2026$177.75$180.3396$175.33$178.361.58M
Sep 29, 2026$176.78$180.9004$174.54$177.731.66M
Sep 28, 2026$174.85$180.05$174.69$177.331.32M
Sep 25, 2026$178.50$179.9699$174.50$177.251.58M
Sep 24, 2026$174.05$181.79$173.50$176.452.57M
Sep 23, 2026$176.21$179.35$174.17$176.311.43M
Sep 22, 2026$172.398$179.43$170.50$177.162.23M
Sep 21, 2026$181.37$181.37$172.86$173.872.62M

Latest GH news

The latest Smart Investors Daily articles mentioning GH.

Stock researchCompany · Overview

GH research

Overview

Company profile and research snapshot.

Company profile

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$93.00
Implied upside
—
Analysts
—
GH recent ratings
DateFirmRatingTarget
Oct 13, 2026Morgan StanleyOverweight—
Oct 7, 2026BarclaysOverweight—
Oct 1, 2026GuggenheimBuy—
Sep 9, 2026UBSBuy—
Sep 8, 2026Rothschild & CoBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 18, 2026

Guardant Health (GH) After Shield And Reveal Data Is The Undervalued Story Still Intact

Guardant Health (GH) is back in focus after new data on its Shield blood test for colorectal cancer screening and Guardant Reveal test for melanoma residual disease were released in October 2026. Investors have taken notice of this Shield and Guardant Reveal data, even as the Guardant Health share price has eased in the short term. The 1-month share price return is down 9.32% and the 7-day share price return is down 5.30%. At the same time, the 1-year total shareholder return of 142.29% and...

Yahoo · Oct 17, 2026

Is Guardant Health (GH) At A Turning Point After Its Patent Setback?

Guardant Health (NasdaqGS:GH) lost a key U.S. patent challenge after the PTAB upheld all 30 claims of TwinStrand's '127 patent. The ruling centers on Duplex Sequencing technology and follows an earlier jury finding of willful patent infringement against Guardant Health. The decision supports ongoing royalties and payments to TwinStrand, increasing legal, operational, and financial pressure around Guardant Health's use of the technology. The PTAB decision upholding TwinStrand's Duplex...

Yahoo · Oct 17, 2026

Is 99% Screening Adherence Altering The Investment Case For Guardant Health (GH)?

Guardant Health reported new data from its Shield blood-based colorectal cancer screening test, including modeling and rural clinic results, indicating very high real world adherence and meaningful impact on screening pathways for average risk adults. The 99% completion rate for Shield in two rural South Carolina clinics highlights how a simple blood draw can address screening gaps in medically underserved communities and reshape demand across Guardant Health's screening franchise. This...

Yahoo · Oct 15, 2026

TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent

SEATTLE, October 15, 2026--TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected Guardant Health, Inc.’s (Nasdaq: GH) challenge to a core patent underlying Duplex Sequencing. In an Oct. 14, 2026, Final Written Decision on remand from the U.S. Court of Appeals for the Federal Circuit, the PTAB ruled in favor of the University of Washington (UW), determin

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By